[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novocure Ltd Ord Sh (NVCR)

Novocure Ltd Ord Sh (NVCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,728,059
  • Shares Outstanding, K 116,446
  • Annual Sales, $ 655,350 K
  • Annual Income, $ -136,230 K
  • EBIT $ -154 M
  • EBITDA $ -163 M
  • 60-Month Beta 0.94
  • Price/Sales 2.71
  • Price/Cash Flow N/A
  • Price/Book 5.25

Options Overview Details

View History
  • Implied Volatility 70.43% (-4.38%)
  • Historical Volatility 116.07%
  • IV Percentile 39%
  • IV Rank 21.91%
  • IV High 152.45% on 03/18/26
  • IV Low 47.41% on 05/21/26
  • Expected Move (DTE 18) 0.86 (5.79%)
  • Put/Call Vol Ratio 0.08
  • Today's Volume 156
  • Volume Avg (30-Day) 380
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 18,611
  • Open Int (30-Day) 19,653
  • Expected Range 13.98 to 15.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.23
  • Number of Estimates 4
  • High Estimate $-0.14
  • Low Estimate $-0.31
  • Prior Year $-0.33
  • Growth Rate Est. (year over year) +30.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.83 +0.07%
on 07/31/26
21.45 -30.82%
on 07/24/26
-0.31 (-2.05%)
since 06/30/26
3-Month
13.43 +10.50%
on 06/23/26
21.45 -30.82%
on 07/24/26
-0.37 (-2.43%)
since 04/30/26
52-Week
9.82 +51.12%
on 02/09/26
21.45 -30.82%
on 07/24/26
+3.87 (+35.28%)
since 07/30/25

Most Recent Stories

More News
NovoCure: Q2 Earnings Snapshot

NovoCure: Q2 Earnings Snapshot

NVCR : 14.84 (-2.56%)
Novocure Reports Second Quarter 2026 Financial Results

Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications CE Mark received for Optune Pax® ...

NVCR : 14.84 (-2.56%)
NovoCure's Profitability Path Gets Its First Real Test After Pancreatic Launch

Barchart Research What to Expect from NVCR Earnings NVCR Generated July 22, 2026 Current Price $15.57 EPS Estimate $$-0.30 Consensus Rating Moderate Buy Average Move 10.36% NovoCure's Profitability Path...

NVCR : 14.84 (-2.56%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR

NEW YORK , July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR).  Such investors are advised...

NVCR : 14.84 (-2.56%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR

NEW YORK , July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR).  Such investors are advised...

NVCR : 14.84 (-2.56%)
Novocure to Report Second Quarter 2026 Financial Results

Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open. Novocure management will host a conference call and...

NVCR : 14.84 (-2.56%)
Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer

The CE Mark is supported by results from the Phase 3 PANOVA-3 trial demonstrating a statistically significant improvement in overall survival (OS) for patients treated with Optune Pax concomitant with...

NVCR : 14.84 (-2.56%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR

NEW YORK , June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised...

NVCR : 14.84 (-2.56%)
NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or “the Company”) (NASDAQ:...

NVCR : 14.84 (-2.56%)
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)

Novocure reported its Phase 3 TRIDENT Trial failed to achieve its primary endpoint of an increase in overall survival for patients at the start of chemoradiation. Shares were down more than 18% midday...

NVCR : 14.84 (-2.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

3rd Resistance Point 16.33
2nd Resistance Point 16.03
1st Resistance Point 15.43
Last Price 14.84
1st Support Level 14.54
2nd Support Level 14.24
3rd Support Level 13.64

See More

52-Week High 21.45
Fibonacci 61.8% 17.01
Fibonacci 50% 15.64
Last Price 14.84
Fibonacci 38.2% 14.26
52-Week Low 9.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.